title: Effects of individual and combined treatment with prostaglandins E2 and F2 alpha on progesterone secretion by ovine luteal cells supplemented with homologous serum lipoproteins in vitro.
abstract: Prostaglandin F2 alpha (PGF2 alpha) is a potent luteolysin, whereas prostaglandin E2 (PGE2) is generally luteotropic in vivo. To establish a model system for investigations of the mechanisms involved in these actions, we examined the effects of individual and combined treatment with PGE2 and PGF2 alpha on basal and ovine LH-stimulated progesterone secretion during long-term incubations conducted with and without supplemental homologous low-density lipoprotein (LDL) as substrate. Effects of both PGF2 and PGF2 alpha were concentration- and time-dependent and were further influenced by the presence of LDL and/or LH in medium. Neither of the prostaglandins exerted any significant effect before 48 h in culture, but distinctly different patterns of response to PGE2 and PGF2 alpha emerged thereafter. Low, but not high, concentrations of PGE2 increased progesterone secretion in the absence of LH, whereas PGF2 alpha (alone and in combination with PGE2) inhibited progesterone production in all medium formulations. The transcriptional inhibitor actinomycin effectively blocked the actions of PGF2 alpha, but had no effect on response to LH or PGE2. These data demonstrate that both the putative luteotropic actions of PGE2 and the potent, luteolytic effects of PGF2 alpha in vivo can be reproduced in long-term cultures of ovine luteal cells in vitro, and they suggest that the mechanism of PGF2 alpha-induced luteolysis may involve new protein synthesis.
authors.affiliation: Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814.
authors.forename: T A
authors.initials: TA
authors.lastname: Fitz
authors.forename: M M
authors.initials: MM
authors.lastname: Marr
authors.forename: D F
authors.initials: DF
authors.lastname: Contois
authors.forename: C E
authors.initials: CE
authors.lastname: Rexroad
authors.forename: M A
authors.initials: MA
authors.lastname: Fritz
mesh_terms: D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology; D015237:Dinoprost / Q000008:administration & dosage / Q000494:pharmacology*; D015232:Dinoprostone / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D066298:In Vitro Techniques; D008074:Lipoproteins / Q000494:pharmacology; D008184:Luteal Cells / Q000187:drug effects* / Q000378:metabolism; D007986:Luteinizing Hormone / Q000494:pharmacology; D011374:Progesterone / Q000378:metabolism; D012756:Sheep
chemical_list: D008074:Lipoproteins; D011374:Progesterone; D007986:Luteinizing Hormone; D015237:Dinoprost; D015232:Dinoprostone